Welcome to Neuropsychopharmacology

Neuropsychopharmacology is an international scientific journal and the official publication of the American College of Neuropsychopharmacology. The journal focuses on clinical and basic science contributions that advance our understanding of the brain and behavior.


NEW NPPR Issue: The 2017 edition of Neuropsychopharmacology Reviews: "The Immunology of Behavior—Exploring the Role of the Immune System in Brain Health and Illness," focuses on the growing appreciation of the immune system in understanding brain and health illness.

Explore the issue | Listen to the podcast


Latest Podcast: "Arbaclofen in Children and Adolescents with Autism Spectrum Disorder:" Autism Spectrum Disorder has been defined by the medical community, but so far, none of the medications available for ASD treat the core symptoms of the disease. Because ASD is genetically linked to Fragile X syndrome, researchers noticed that in a mouse model, the drug arbaclofen reduced what would be core symptoms of autism, such as combatting social avoidance and improving social function. A randomized placebo-controlled trial was conducted to test this idea and the results were recently published in Neuropsychopharmacology.

Read the article | Listen to the podcast

About the cover

Volume 42, No 8
July 2017

ISSN: 0893-133X
EISSN: 1740-634X

2016 Impact Factor 6.403*
12/142 Psychiatry
21/258 Neurosciences
14/256 Pharmacology and Pharmacy

Editor:
William A. Carlezon Jr., PhD

*2016 Journal Citation Reports® Science Edition (Clarivate Analytics, 2017)

Archival Perspectives - Highlighting our most-cited research from past issues

Twenty years ago this month:
Ehlers CL, Somes C, Lopez A et al (1997). Electrophysiological actions of neuropeptide Y and its analogs: New measures for anxiolytic therapy?. Neuropsychopharmacology 17: 34-43 (Times cited: 64)

Hertel P, Nomikos GG, Schilstrom B et al (1997). Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: Role of alpha(2)-adrenoceptor antagonism. Neuropsychopharmacology 17: 44-55 (Times cited: 64)

 

Ten years ago this month:
Czeh B, Mueller-Keuker JIH, Rygula R et al (2007). Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: Hemispheric asymmetry and reversal by fluoxetine treatment. Neuropsychopharmacology 32: 1490-1503 (Times cited: 166)

Five years ago this month:
Wittfoth-Schardt D, Grunding J, Wittfoth M et al (2012). Oxytocin Modulates Neural Reactivity to Children's Faces as a Function of Social Salience. Neuropsychopharmacology 37: 1799-1807 (Times cited: 47)

See the full history on our archival perspectives page.

NEWS AND ANNOUNCEMENTS 

Neuropsychopharmacology is happy to announce our newly appointed Social Media Editor Gretchen Neigh. Follow us now on Facebook and Twitter!

In 2013, the ACNP established the "Neuropsychopharmacology Editors Award for a Transformative Original Report" (also known as the NEATOR Award). This award is intended to recognize and honor the best original paper published in Neuropsychopharmacology during the previous calendar year. This year's winning paper, which was announced at the 55th Annual Meeting of the ACNP meeting, is Sex Differences in Depressive and Socioemotional Responses to an Inflammatory Challenge: Implications for Sex Differences in Depression by Naomi I Eisenberger.


Neuropsychopharmacology is committed to a streamlined submission process for your manuscript. See our Instructions for Authors, which outline some updated details for manuscript preparation and submission. Of note, as of November 2015: The journal requires submitted CONSORT checklists for all clinical trials, and for all papers, Authorship Disclosure forms are no longer required.


Open Access Funding

Visit Springer Nature's open access funding page for information about research funders and institutions that provide funding for open access. Springer Nature also offers an article processing charge (APC) support service to make it easier for Neuropsychopharmacology authors to discover and apply for open access funding. For advice on what funding is available to you and help in approaching funders and institutions, please contact us at openaccess@nature.com.

For more information about Springer Nature's open access publishing options and policies, please see our open access homepage.


Neuroscience Peer Review Consortium logo

On November 6, 2014, Neuropsychopharmacology was accepted into the Neuroscience Peer Review Consortium. The purpose of the NPRC is to decrease the time and effort involved in the peer review process, and reduce the burden placed on reviewers. NPRC member journals agree to transfer manuscript reviews upon the author's request. A flowchart of the transfer process and a list of member journals can be found on the NPRC website.


Visit the ACNP Discussion Forum to hear more from researchers and authors about NPP articles.


Press releases

Hope for people who struggle after suffering brain trauma.

Neuropsychopharmacology does frequent press releases that can be found on the detailed press release page.